Cancer remains one of the most strong challenges existing in modern medicine as of today, making it necessary to innovate strategies to combat its relentless progression. Out of the many strategies ...

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC).

This past February, for example, Sugen, a division of Peapack, NJ-based Pharmacia, announced it was aborting its Phase III colorectal cancer clinical trial of SU5416, as no clinical benefit was found.

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...

Researchers from Washington University School of Medicine performed studies to assess the role of ZBTB46, a repressive transcription factor and a marker for classical dendritic cells (DCs), in tumor ...

In the past few years, the media have written numerous, hopeful stories of how scientists are stifling tumors by inhibiting blood vessel growth. But the drugs based on this strategy--Endostatin, ...

Douglas Hanahan (left), the former Director of the Swiss Institute for Experimental Cancer Research (ISREC) at EPFL, works in the Agora Translational Cancer Research Center as a member of the Ludwig ...